Your browser doesn't support javascript.
loading
N-BLR, a primate-specific non-coding transcript leads to colorectal cancer invasion and migration.
Rigoutsos, Isidore; Lee, Sang Kil; Nam, Su Youn; Anfossi, Simone; Pasculli, Barbara; Pichler, Martin; Jing, Yi; Rodriguez-Aguayo, Cristian; Telonis, Aristeidis G; Rossi, Simona; Ivan, Cristina; Catela Ivkovic, Tina; Fabris, Linda; Clark, Peter M; Ling, Hui; Shimizu, Masayoshi; Redis, Roxana S; Shah, Maitri Y; Zhang, Xinna; Okugawa, Yoshinaga; Jung, Eun Jung; Tsirigos, Aristotelis; Huang, Li; Ferdin, Jana; Gafà, Roberta; Spizzo, Riccardo; Nicoloso, Milena S; Paranjape, Anurag N; Shariati, Maryam; Tiron, Aida; Yeh, Jen Jen; Teruel-Montoya, Raul; Xiao, Lianchun; Melo, Sonia A; Menter, David; Jiang, Zhi-Qin; Flores, Elsa R; Negrini, Massimo; Goel, Ajay; Bar-Eli, Menashe; Mani, Sendurai A; Liu, Chang Gong; Lopez-Berestein, Gabriel; Berindan-Neagoe, Ioana; Esteller, Manel; Kopetz, Scott; Lanza, Giovanni; Calin, George A.
Afiliação
  • Rigoutsos I; Computational Medicine Center, Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA, USA. isidore.rigoutsos@jefferson.edu.
  • Lee SK; Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Nam SY; Present address: Institute of Gastroenterology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
  • Anfossi S; Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Pasculli B; Gastroenterology, Department of Internal Medicine, Kyungpook National University Medical School, Daegu, Korea.
  • Pichler M; Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Jing Y; Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Rodriguez-Aguayo C; Present address: Laboratory of Oncology, IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, FG, Italy.
  • Telonis AG; Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Rossi S; Present address: Division of Oncology, Medical University of Graz, Graz, Austria.
  • Ivan C; Computational Medicine Center, Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA, USA.
  • Catela Ivkovic T; Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Fabris L; Center for RNA interference and non-coding RNA, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Clark PM; Computational Medicine Center, Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA, USA.
  • Ling H; Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Shimizu M; Present address: Institute of Oncology Research (IOR), Research Division of the Oncology Institute of Southern Switzerland (IOSI), Bellinzona, Switzerland.
  • Redis RS; Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Shah MY; Center for RNA interference and non-coding RNA, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Zhang X; Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Okugawa Y; Department of Molecular Medicine, Ruder Boskovic Institute, Zagreb, Croatia.
  • Jung EJ; Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Tsirigos A; Department of Pathology and Laboratory Medicine, The Children's Hospital of Philadelphia, Philadelphia, PA, USA.
  • Huang L; Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Ferdin J; Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Gafà R; Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Spizzo R; Present address: ProQR Therapeutics, Leiden, Netherlands.
  • Nicoloso MS; Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Paranjape AN; Center for RNA interference and non-coding RNA, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Shariati M; Department of Gynecologic Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Tiron A; Center for Gastrointestinal Research, and Center for Translational Genomics and Oncology, Baylor Scott & White Research Institute and Charles A. Sammons Cancer Center, Baylor University Medical Center, Dallas, TX, USA.
  • Yeh JJ; Department of Surgery, School of Medicine, Gyeongsang National University, Jin-ju, South Korea.
  • Teruel-Montoya R; Department of Pathology, NYU Langone Medical Center, New York, NY, 10016, USA.
  • Xiao L; Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Melo SA; Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Menter D; Present address: Institute of Biochemistry, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.
  • Jiang ZQ; Department of Morphology, Surgery and Experimental Medicine, University of Ferrara, Ferrara, Italy.
  • Flores ER; Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Negrini M; Present address: CRO, National Cancer Institute, 33081, Aviano, Italy.
  • Goel A; Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Bar-Eli M; Present address: CRO, National Cancer Institute, 33081, Aviano, Italy.
  • Mani SA; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Liu CG; Present address: National Cancer Institute, Bethesda, MD, USA.
  • Lopez-Berestein G; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Berindan-Neagoe I; Department of Medicine, Nassau University Medical Center, 2201 Hempstead Tpke, East Meadow, NY, 11554, USA.
  • Esteller M; Departments of Surgery and Pharmacology, UNC Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
  • Kopetz S; Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Lanza G; Present address: Centro Regional de Hemodonación, Universidad de Murcia, IMIB-Arrixaca, CIBEER (CB15/00055), Murcia, Spain.
  • Calin GA; Division of Quantitative Science, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Genome Biol ; 18(1): 98, 2017 05 24.
Article em En | MEDLINE | ID: mdl-28535802
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Colorretais / Leucemia Linfocítica Crônica de Células B / Regulação Neoplásica da Expressão Gênica / Transição Epitelial-Mesenquimal / RNA Longo não Codificante Tipo de estudo: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Aged80 Idioma: En Ano de publicação: 2017 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Colorretais / Leucemia Linfocítica Crônica de Células B / Regulação Neoplásica da Expressão Gênica / Transição Epitelial-Mesenquimal / RNA Longo não Codificante Tipo de estudo: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Aged80 Idioma: En Ano de publicação: 2017 Tipo de documento: Article